Clinical Trials on Parosteal Osteosarcoma in China

Total 52 results

Beijing Immunochina Medical Science & Technology...
Guangdong Provincial People's Hospital

Not yet recruiting

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma

China
Peking University People's Hospital

Recruiting

Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

Osteosarcoma of Pelvis

China
Yuxi Su

Completed

3D Printed Personalized Extendable Prosthesis

Osteosarcoma in Children

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Osteosarcoma, Advanced

China
Peking University People's Hospital
Peking University Shougang Hospital

Completed

Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study

Pulmonary Disease | Osteosarcoma Metastatic | Survival | Resectable Sarcoma

China
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; OrigiMed

Completed

Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS (CSSG-02)

Osteosarcoma

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Osteosarcoma

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Qilu Hospital... and other collaborators

Recruiting

Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma (Li2CO3)

Osteosarcoma

China
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Sarcoma | Osteosarcoma

China
The First Affiliated Hospital of Xinxiang Medical...

Not yet recruiting

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Osteosarcoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

Osteosarcoma

China
West China Hospital

Recruiting

Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma

Osteosarcoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Osteosarcoma

China
Sun Yat-sen University

Recruiting

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sarcoma

China
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Soft Tissue Sarcoma | Osteosarcoma

China
Peking University People's Hospital

Unknown

PD-L1 Expression in Advanced Osteosarcoma

Progression | Survival

China
Ruijin Hospital

Recruiting

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial (PROMIS)

Osteosarcoma

China
Peking University People's Hospital

Recruiting

Irinotecan and Temozolomide for Ewing Sarcoma

Ewing Sarcoma

China
Peking University People's Hospital

Unknown

TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss (TQBSP)

Safety Issues | Efficacy, Self

China
Peking University People's Hospital

Unknown

Anlotinib and Irinotecan for Ewing Sarcoma

Ewing's Tumor Metastatic

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Proteomics Research of Osteosarcoma (PROS001)

Osteosarcoma | Proteomics

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...

Recruiting

Combination Immunotherapy Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Fudan University

Terminated

Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)

Ewing's Sarcoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Peking University People's Hospital
Shanghai Hansen Biopharmaceutical Technology Co., Ltd; MEDx Translational Medicine...

Recruiting

Soluble B7-H3 as a Biomarker for Osteosarcoma

Progression | Osteosarcoma | Surveillance | Biomarker

China
Peking University People's Hospital
Peking University; Northwestern University

Unknown

Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab (EBAOFC)

Drug Resistance to Famitinib and Camrelizumab | Biomarkers for Efficacy and Toxicity

China
Second Affiliated Hospital, School of Medicine,...
Peking University People's Hospital; Qilu Hospital of Shandong University; Ruijin... and other collaborators

Not yet recruiting

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Osteosarcoma

China, Korea, Republic of
Shandong Simcere-Medgenn Bio-pharmaceutical Co....

Unknown

A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma

Osteosarcoma

China
GUO WEI

Completed

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Osteosarcoma | Metastasis

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)

Toxicity | Overall Survival | Progression-free Survival | Clinical Benefit Rate

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Lung Metastases | Tumor Necrosis

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
Ruijin Hospital

Active, not recruiting

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)

Pulmonary Metastases | Osteosarcoma | Apatinib

China
Changye Zou

Completed

Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient

Osteosarcoma | Pediatric | Lower Limb Injury | Outcome

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Osteosarcoma | Other Solid Tumors

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study (RASS)

Sarcoma | Head and Neck Cancer | Soft Tissue and Bone Tumor

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Peking University People's Hospital
Chinese Sarcoma Study Group

Recruiting

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma (MAPAC)

Osteosarcoma | Chemotherapy Effect | Survival | Toxicity, Drug

China
Peking University People's Hospital
Peking University Shougang Hospital

Suspended

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma (AIEO)

Effect of Drug | Toxicity, Drug

China
Shanghai Yunying Medical Technology
Xi'an Honghui Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

Sarcoma | Osteosarcoma | Sarcoma,Soft Tissue | Bone Tumor

China
Shanghai Yunying Medical Technology
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Bone Tumor

China
Peking University People's Hospital

Completed

Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma

Overall Survival | Pathological Response | Event-free Survival | Local-recurrence Free Survival

China
Peking University People's Hospital
Peking University Shougang Hospital

Completed

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Effect of Drug | Toxicity, Drug | Secondary Resistance

China
Peking University People's Hospital
Peking University; Northwestern University; University of Chicago

Unknown

Epigenetic Biomarker for Osteosarcoma

Histologic Response (Tumor Necrosis Rate) | Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Progression-free Survival, PFS | Overall Survival, OS

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

IBI188 Combination Therapy in Solid Tumors

Osteosarcoma | Lung Adenocarcinoma | Solid Tumors

China
Ruijin Hospital

Completed

Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma

Pulmonary Metastases | Osteosarcoma

China
Ruijin Hospital

Active, not recruiting

Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma

Osteosarcoma | Lung Metastases

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

Myocardial Injury | Osteosarcoma | Cardiotoxicity | Doxorubicin Induced Cardiomyopathy | Chemotherapy Induced Systolic Dysfunction

China

Clinical Trials on Parosteal Osteosarcoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations